Drug Trial Radar · NCT06161688
Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
Last checked: Nov 20, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
40
Actual
Start
Apr 9, 2024
Primary completion
Dec 20, 2024
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Timothy HenrichAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shionogi Inc.
- First posted
- Dec 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate long COVID symptoms. This trial will study the safety and efficacy of Ensitrelvir (S-217622), an antiviral, to treat individuals with Long COVID in an adult population.
Conditions
- Long COVID
- Post Acute Sequelae of COVID-19
- Post-Acute COVID-19
Interventions
EnsitrelvirDrug
Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days
PlaceboOther
Matching placebo for Ensitrelvir
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Physical Health Summary ScoreTime frame: Day 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UCSF/Zuckerberg San Francisco General Hospital
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.